A brief recap of Genetics/Genomics news the week of Aug 31, 2018: Perosnalize Medicine Coalition, Enzo Biochem, Hoosier Cancer Research Network, Scor Global Life, and ALCF
The company plans to submit its 650- to 700-gene panel, which will include microsatellite instability testing, to the FDA for approval as a companion diagnostic.
Researchers profiled cancer gene mutations, expression, protein patterns, and other features in 23 recurrent or metastatic cases of olfactory neuroblastoma.
The firm has been developing several new tests that are based on its ADAPT aptamer profiling technology.
The Irving, Texas-based company claims that three of Foundation Medicine's cancer molecular profiling tests infringe five of its US patents.
The study will perform next-generation sequencing on archival tumor tissue from 200 individuals with metastatic urothelial cancer.
The companies will perform tumor profiling to identify patients with genetic abnormalities that could make them eligible for treatment in the NCI study.
There are now 100 sites in the US participating in the basket study, and soon trials with similar approaches will be available in Canada and 13 other countries.
Though considered potential antibody alternatives, these reagents are more likely to succeed in new applications for which conventional tools are poorly suited.
Caris will be on the lookout for pancreatic cancer patients with low DNA mismatch repair protein expression.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.